Can we afford the NHS in future?
BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d4321 (Published 12 July 2011) Cite this as: BMJ 2011;343:d4321In an article for the Daily Telegraph in June, Andrew Lansley, England’s health secretary, made an interesting prediction. By 2030, he said (referring to England), “If things carry on unchanged, this would mean real terms health spending more than doubling to £230 billion.” He also stated that, “This is something we simply cannot afford.”1 It is of course then a short step to an argument that the NHS must change (because unchanged equals unaffordable) and that the change it needs are the secretary of state’s reforms. This is a version of the “politician’s syllogism”:
1. The NHS must change (otherwise it is unaffordable)
2. This (the reforms) is change
3. Therefore we must do this (the reforms).
As the “pause” and subsequent changes to the NHS reforms have shown, such logic is debatable. But perhaps the premise is also questionable. £230bn (€260bn; $379bn) is certainly a lot of money—as Mr Lansley points out, that’s equivalent to spending at a rate of over £7000 a second. But in what sense is it actually unaffordable?
If the NHS in England were currently consuming £230bn then as a proportion of (England’s) gross domestic product (GDP) this would amount to 18% of GDP devoted to health. That compares with the actual figure of 8.5% of GDP. But the £230bn is not spending now, but what spending might be in 20 years’ time. It is equivalent to average real increases in spending of just over 4% a year—a bit more than the long run average for the NHS since 1948.
Crucially, however, the country’s capacity to afford higher spending will change over time. Over the next 20 years it is likely that the economy will grow in value. Between 2011 and 2015 for example, the UK economy is forecast to expand by nearly 30% in cash terms—around 14% in real terms and an average of around 2.5% a year.2 It is not unreasonable to assume that this real growth will continue for the next 20 years such that GDP (at today’s prices) will rise from £1.5tr this year to £2.5tr in 2030.
Assuming England’s share of this remains the same (at around 84%), then £230bn as a proportion of GDP in 2030 will amount to 10.9%. This is certainly more than is currently spent—2.4 percentage points of GDP more—but is it “unaffordable”? Adding private spending on health care to NHS spend (to enable better comparison with other countries), total spend in 2030 could be around 12.4% of GDP (up from around 10% this year). This would make England the highest spending country in the Organisation for Economic Cooperation and Development bar the United States—but only assuming no other country increased its spending on healthcare (fig 1⇓). Even in 2009, seven of the EU-15 countries spent over 10% of GDP on healthcare. The highest spender—the Netherlands—devoted 12% of its GDP to healthcare (fig 2⇓.
Fig 1 Possible future English healthcare spending 2010-30 as proportion of GDP.3 Figures are hypothetical and assume English private spending is1.5% of GDP
Fig 2 Total healthcare spending of EU-15 countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Sweden, and UK) as proportion of GDP, 1960-2008.3 Unweighted average=sum of percentages/number of countries submitting data in each year
Spending on health will be a matter of choice, not affordability. The real question to ask about health spending is what we think we might get in return as a result of forgoing the benefits of spending increasing amounts of our wealth on other things. For example, is the two year increase in life expectancy at birth we might possibly enjoy as a result of higher health spending (fig 3⇓) worth the benefits we will not get to enjoy from spending more on education, food, or housing?
Fig 3 Higher health spending, longer lives? Data on the relation between spending and life expectancy from OECD countries3
Notes
Cite this as: BMJ 2011;343:d4321
Footnotes
Competing interests: The author has completed the ICJME unified disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from him) and declares no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.
Provenance and peer review: Commissioned; externally peer reviewed.
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.